Q1 2025 EPS Estimates for Corcept Therapeutics Incorporated Lifted by Analyst (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORTFree Report) – Analysts at Zacks Research increased their Q1 2025 EPS estimates for Corcept Therapeutics in a research note issued to investors on Wednesday, May 29th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $0.24 per share for the quarter, up from their prior forecast of $0.23. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.95 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.28 EPS, Q3 2025 earnings at $0.31 EPS, FY2025 earnings at $1.23 EPS and Q1 2026 earnings at $0.49 EPS.

A number of other equities analysts have also weighed in on CORT. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 3rd. Truist Financial boosted their price target on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Corcept Therapeutics in a research report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Buy” and an average target price of $40.10.

Check Out Our Latest Report on Corcept Therapeutics

Corcept Therapeutics Stock Down 3.3 %

CORT stock opened at $30.17 on Friday. The stock has a market capitalization of $3.14 billion, a P/E ratio of 28.46 and a beta of 0.50. The firm has a 50-day simple moving average of $25.50 and a 200-day simple moving average of $25.35. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $34.28.

Corcept Therapeutics (NASDAQ:CORTGet Free Report) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.04. The business had revenue of $146.80 million during the quarter, compared to analysts’ expectations of $141.19 million. Corcept Therapeutics had a net margin of 22.38% and a return on equity of 24.19%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 earnings per share.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds have recently made changes to their positions in the stock. FNY Investment Advisers LLC purchased a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $32,000. Gladius Capital Management LP purchased a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $36,000. GAMMA Investing LLC boosted its position in shares of Corcept Therapeutics by 90.6% during the 1st quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 579 shares during the period. Planned Solutions Inc. purchased a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $45,000. Finally, Headlands Technologies LLC purchased a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $47,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Activity

In other news, insider Sean Maduck sold 25,953 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $25.01, for a total value of $649,084.53. Following the completion of the sale, the insider now owns 85,222 shares of the company’s stock, valued at approximately $2,131,402.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Sean Maduck sold 25,953 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $25.01, for a total value of $649,084.53. Following the completion of the sale, the insider now owns 85,222 shares of the company’s stock, valued at approximately $2,131,402.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $25.30, for a total transaction of $55,660.00. The disclosure for this sale can be found here. Insiders sold a total of 130,372 shares of company stock valued at $3,493,515 in the last 90 days. Company insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Read More

Earnings History and Estimates for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.